Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Boehringer Ingelheim
 More »

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    biopharma firms promulgating late-stage clinical results. Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and Roche/Genentech are among those ...
    5-16-2013
  • Biotechs Need to Walk the Walk on Drug Value
    ... institutions. Two months later, 10 pharma giants-AbbVie, AstraZeneca (AZ), Boehringer Ingelheim, Bristol-Myers Squibb (BMS), GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer, ...
    5-15-2013
  • Companion Diagnostics: 52 Pick-Up
    ... CDx Under FDA Review Qiagen and Boehringer Ingelheim Submission announced January 15; agreement announced May 29, 2009 by BI and DxS, since acquired by Qiagen . therascreen ® EGFR ...
    5-9-2013
  • OBT Joins Boehringer Ingelheim in Cancer Drug Collaboration
    Oxford BioTherapeutics (OBT) will develop new cancer drugs with Boehringer Ingelheim (BI) by identifying new antibody targets, then granting BI rights to develop and commercialize ...
    4-29-2013
  • Hormone Holds Promise for Replacing Insulin Injections
    ... In addition to CureBeta, Evotec has long-term discovery alliances with partners that include Bayer, Boehringer Ingelheim, CHDI, Genentech, MedImmune/AstraZeneca, and Ono ...
    4-26-2013
  • GEN | Biolinks
    ... Alabama Biotechnology Ireland BioTek Biotex Biotron bluebird bio BMG Labtech Boehringer Ingelheim Boehringer Ingelheim Brandeis University Brigham Young University Bristol-Myers ...
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    institutions. Two months later, 10 pharma giants-AbbVie, AstraZeneca (AZ), Boehringer Ingelheim, Bristol-Myers Squibb (BMS), GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer, ...
    4-22-2013
  • Biosimilars: 10 Drugs to Watch
    ... Amgen: Biosimilar in active development Boehringer Ingelheim: BI695501 completed Phase I trial in New Zealand, studying the biosimilar's safety and pharmacokinetics compared to ...
    4-22-2013
  • Pathway Analysis to Decipher Data
    ... According to Joshua Apgar, Ph.D., principal scientist of systems biology, department of immunology and inflammation at Boehringer Ingelheim Pharmaceuticals, their use of ...
    4-15-2013
  • Betting on Baculovirus Expression
    ... Fuad T. Haddadin, Ph.D., senior scientist at Boehringer Ingelheim Vetmedica, works on the process development and improvement of biological vaccines, with a focus on the ...
    3-15-2013
  • Qiagen, Lilly Take on Companion Diagnostics
    therascreen® EGFR RGQ PCR Kit test to the FDA as a proposed companion diagnostic to guide treatment with a new investigational oncology compound developed by Boehringer Ingelheim. ...
    2-14-2013
  • ChemAxon Boosts Boehringer Ingelheim toward Next-Gen Cheminformatics
    Boehringer Ingelheim has chosen ChemAxon's chemistry software platform for multiple applications across research and development, supporting in-house activities and work with ...
    2-14-2013
  • Tying Up Loose Ends in Cell-Line Development
    Ph.D., associate director for cell line and cell culture development at Boehringer Ingelheim, will make the case for automation-driven cell-line screening with his company's ...
    2-1-2013
  • Type 2 Diabetes Drugs Drive Sector Growth
    ... In January, Boehringer Ingelheim and Eli Lilly trumpeted topline Phase III results showing that once-daily 10 and 25 mg dosages of empagliflozin met the trial's primary efficacy ...
    2-1-2013
  • Single-Use Systems Entice Multiple Users
    Yet, despite growing adoption industry-wide, penetration of single-use equipment throughout large organizations has been uneven. Boehringer Ingelheim recently developed a program ...
    1-15-2013

  • Journal Articles

  • Effects of Porcine Reproductive and Respiratory Syndrome Virus...
    Wasin Charerntantanakul, Ratree Platt, James A. Roth
    Viral Immunology
    T cells cultured with monocytes infected with virulent PRRSV (VR-2385, SDSU-73, and VR-2332), but not with a vaccine strain (Ingelvac PRRS MLV; Boehringer Ingelheim Vetmedica, St. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll